| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0969-8051(03)00033-7 |
| P698 | PubMed publication ID | 12900284 |
| P2093 | author name string | Brechbiel MW | |
| Ma D | |||
| Chappell LL | |||
| Milenic DE | |||
| Garmestani K | |||
| Beitzel MP | |||
| Venditto V | |||
| P2860 | cites work | Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril | Q29618344 |
| Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma | Q33340348 | ||
| Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy | Q33941767 | ||
| Novel chelating agents for potential clinical applications of copper | Q34489850 | ||
| Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N', N'',N'''-tetraacetic acid-functionalized peptides for radioimmunotherapy. | Q41613459 | ||
| Human colonic adenocarcinoma cells. I. Establishment and description of a new line | Q42803939 | ||
| An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. | Q43582043 | ||
| Chelators for radioimmunotherapy: I. NMR and ab initio calculation studies on 1,4,7,10-tetra(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO4Pr) and 1,4,7-tris(carboxymethyl)-10-(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO3A1Pr). | Q43697001 | ||
| In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications | Q44007089 | ||
| A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates | Q46398674 | ||
| Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. | Q50513647 | ||
| The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex | Q56832818 | ||
| Structure and dynamics of all of the stereoisomers of europium complexes of tetra(carboxyethyl) derivatives of dota: ring inversion is decoupled from cooperative arm rotation in the RRRR and RRRS isomers | Q60171767 | ||
| Tumour targeting with radiolabelled macrocycle–antibody conjugates | Q60171856 | ||
| Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. | Q64975285 | ||
| Convenient synthesis of bifunctional tetraaza macrocycles | Q68031784 | ||
| Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin | Q70290393 | ||
| Improved synthesis of the bifunctional chelating agent 1,4,7,10-tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tri s(acetic acid)cyclododecane (PA-DOTA) | Q73346804 | ||
| Purification of p-nitrobenzyl C-functionalized diethylenetriamine pentaacetic acids for clinical applications using anion-exchange chromatography | Q73482799 | ||
| Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA | Q73881014 | ||
| Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications | Q74013187 | ||
| A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin | Q74379422 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 581-595 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Nuclear Medicine and Biology | Q7067979 |
| P1476 | title | Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins | |
| P478 | volume | 30 |
| Q38663041 | Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease |
| Q36939055 | Convenient Synthesis and Evaluation of Heptadentate Bifunctional Ligand for Radioimmunotherapy Applications |
| Q35098222 | Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications |
| Q40560909 | Generation of DOTA-conjugated antibody fragments for radioimmunoimaging |
| Q37209655 | H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy |
| Q38156660 | Matching chelators to radiometals for radiopharmaceuticals |
| Q57567743 | Optimized preparation and preliminary evaluation of [64Cu]–DOTA–trastuzumab for targeting ErbB2/Neu expression |
| Q39414818 | Positron emission tomography of 64Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. |
| Q36881146 | Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies |
| Q53087436 | Preclinical evaluation of holmium-166 labeled anti-VEGF-A(Bevacizumab). |
| Q34669139 | Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma |
| Q42096470 | Production and Quality Control of [(67)Ga]-DOTA-trastuzumab for Radioimmunoscintigraphy |
| Q36008285 | Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors |
| Q37515337 | Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods |
| Q35224087 | Synthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of (90)Y and (177)Lu |
| Q36247600 | Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy |
| Q36691184 | Targeted alpha-therapy: past, present, future? |
| Q39182026 | The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab. |
| Q36903804 | The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis |
| Q35028126 | Towards translation of 212Pb as a clinical therapeutic; getting the lead in! |
| Q36372777 | Transferrin conjugates of triazacyclononane-based bifunctional NE3TA chelates for PET imaging: Synthesis, Cu-64 radiolabeling, and in vitro and in vivo evaluation. |
Search more.